506 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by KBC Group NV

KBC Group NV acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 506 shares of the company’s stock, valued at approximately $155,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Contravisory Investment Management Inc. acquired a new position in Medpace in the 4th quarter valued at about $26,000. RiverPark Advisors LLC acquired a new position in shares of Medpace during the fourth quarter worth about $26,000. GAMMA Investing LLC acquired a new position in shares of Medpace during the fourth quarter worth about $30,000. McGlone Suttner Wealth Management Inc. acquired a new position in shares of Medpace during the fourth quarter worth about $33,000. Finally, Principal Securities Inc. acquired a new position in shares of Medpace during the fourth quarter worth about $68,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of MEDP stock opened at $405.68 on Tuesday. The business’s fifty day moving average price is $393.84 and its 200 day moving average price is $355.74. Medpace Holdings, Inc. has a 1-year low of $207.83 and a 1-year high of $421.00. The firm has a market capitalization of $12.57 billion, a PE ratio of 41.35, a P/E/G ratio of 1.98 and a beta of 1.39.

Medpace (NASDAQ:MEDPGet Free Report) last posted its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. Medpace’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.27 earnings per share. Equities research analysts expect that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August J. Troendle sold 5,695 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the sale, the chief executive officer now owns 654,656 shares of the company’s stock, valued at $258,909,901.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the sale, the chief executive officer now directly owns 791,541 shares in the company, valued at $317,162,563.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 5,695 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total value of $2,252,315.55. Following the completion of the sale, the chief executive officer now owns 654,656 shares in the company, valued at $258,909,901.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,973 shares of company stock valued at $11,960,425. Insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MEDP. Mizuho began coverage on Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 target price for the company. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Friday. Guggenheim boosted their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird upped their price target on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and upped their price target for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Medpace currently has an average rating of “Moderate Buy” and an average price target of $443.14.

Get Our Latest Report on Medpace

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Further Reading

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.